Published in Cancer Cell on January 06, 2011
MicroOrganoSphere Drug Screen Pilot Trial in Colorectal Cancer (CRC) | NCT05189171
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell (2011) 7.32
PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov (2014) 4.81
The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer (2012) 4.72
mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov (2011) 4.05
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet (2013) 4.03
Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell (2012) 3.77
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene (2011) 3.59
Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol (2013) 3.57
Tumor adaptation and resistance to RAF inhibitors. Nat Med (2013) 3.11
PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov (2012) 2.89
FOXOs: signalling integrators for homeostasis maintenance. Nat Rev Mol Cell Biol (2013) 2.83
Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling. Cancer Discov (2014) 2.79
Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell (2012) 2.71
Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov (2013) 2.65
Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov (2012) 2.53
ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell (2014) 2.44
Targeted therapies for breast cancer. J Clin Invest (2011) 2.22
Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res (2011) 2.19
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer (2015) 2.10
Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol (2011) 2.10
Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. Cancer Discov (2012) 1.97
Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer. Sci Signal (2013) 1.96
MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res (2012) 1.87
PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res (2012) 1.83
Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ. Cancer Cell (2014) 1.73
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science (2016) 1.73
MicroRNA-21 orchestrates high glucose-induced signals to TOR complex 1, resulting in renal cell pathology in diabetes. J Biol Chem (2011) 1.70
Converting cancer therapies into cures: lessons from infectious diseases. Cell (2012) 1.65
Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is mediated by Pim-1. Cancer Res (2013) 1.65
Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. Cancer Cell (2016) 1.61
Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy. Genes Dev (2012) 1.60
Emerging targeted agents in metastatic breast cancer. Nat Rev Clin Oncol (2013) 1.59
Identifying and quantifying heterogeneity in high content analysis: application of heterogeneity indices to drug discovery. PLoS One (2014) 1.58
Negative feedback and adaptive resistance to the targeted therapy of cancer. Cancer Discov (2012) 1.57
PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1. Proc Natl Acad Sci U S A (2013) 1.57
Overcoming implementation challenges of personalized cancer therapy. Nat Rev Clin Oncol (2012) 1.56
Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer. Cancer Cell (2014) 1.55
The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol (2011) 1.55
Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation. Breast Cancer Res (2011) 1.54
Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains. Cell Rep (2015) 1.52
Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. Clin Cancer Res (2012) 1.50
Genomic complexity and AKT dependence in serous ovarian cancer. Cancer Discov (2012) 1.50
Targeting Translation Initiation Bypasses Signaling Crosstalk Mechanisms That Maintain High MYC Levels in Colorectal Cancer. Cancer Discov (2015) 1.48
Interplay between FOXO, TOR, and Akt. Biochim Biophys Acta (2011) 1.47
Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer. Cell Rep (2016) 1.46
Rapamycin: one drug, many effects. Cell Metab (2014) 1.41
Molecular pathways: HER3 targeted therapy. Clin Cancer Res (2014) 1.41
PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control. Genes Cancer (2010) 1.38
Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proc Natl Acad Sci U S A (2013) 1.36
The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer. Br J Cancer (2011) 1.34
Eph receptor signaling and ephrins. Cold Spring Harb Perspect Biol (2013) 1.33
PUMA and BIM are required for oncogene inactivation-induced apoptosis. Sci Signal (2013) 1.28
Will PI3K pathway inhibitors be effective as single agents in patients with cancer? Oncotarget (2011) 1.26
Beyond BRAF: where next for melanoma therapy? Br J Cancer (2014) 1.26
Impact of genetic dynamics and single-cell heterogeneity on development of nonstandard personalized medicine strategies for cancer. Proc Natl Acad Sci U S A (2012) 1.25
PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. Asian J Androl (2014) 1.23
Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy. Cancer Cell (2015) 1.21
Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Sci Signal (2014) 1.20
Navigating cancer network attractors for tumor-specific therapy. Nat Biotechnol (2012) 1.18
Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function. Clin Cancer Res (2012) 1.17
Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors. Cancer Res (2012) 1.17
RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J Clin Invest (2013) 1.16
Drugging PI3K in cancer: refining targets and therapeutic strategies. Curr Opin Pharmacol (2015) 1.16
Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proc Natl Acad Sci U S A (2014) 1.15
Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. Proc Natl Acad Sci U S A (2012) 1.15
Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Mol Cancer (2012) 1.14
Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers. Cancer Res (2013) 1.14
Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation. Cancer Discov (2013) 1.13
Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation. Breast Cancer Res (2013) 1.12
An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer Res (2013) 1.11
The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer. J Natl Compr Canc Netw (2013) 1.11
PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system. Clin Cancer Res (2013) 1.11
Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions. Oncotarget (2012) 1.11
Mechanism-based cancer therapy: resistance to therapy, therapy for resistance. Oncogene (2014) 1.10
Antagonism between FOXO and MYC Regulates Cellular Powerhouse. Front Oncol (2013) 1.10
Distinct roles of AKT isoforms in regulating β1-integrin activity, migration, and invasion in prostate cancer. Mol Biol Cell (2012) 1.09
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Sci Transl Med (2015) 1.09
Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathol Appl Neurobiol (2012) 1.08
Evolution of androgen receptor targeted therapy for advanced prostate cancer. Nat Rev Clin Oncol (2014) 1.08
De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discov (2013) 1.07
Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. EMBO Rep (2015) 1.07
Adaptive stress signaling in targeted cancer therapy resistance. Oncogene (2015) 1.07
Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy. Invest Ophthalmol Vis Sci (2011) 1.07
Combination therapy targeting Akt and mammalian target of rapamycin improves functional outcome after controlled cortical impact in mice. J Cereb Blood Flow Metab (2011) 1.06
Ten things you should know about protein kinases: IUPHAR Review 14. Br J Pharmacol (2015) 1.06
VEGF/neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-IR define a novel mechanism of aggressive prostate cancer. Cancer Discov (2012) 1.06
Targeting the oncogenic MUC1-C protein inhibits mutant EGFR-mediated signaling and survival in non-small cell lung cancer cells. Clin Cancer Res (2014) 1.05
PTEN is a protein tyrosine phosphatase for IRS1. Nat Struct Mol Biol (2014) 1.05
Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models. Breast Cancer Res (2013) 1.04
A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors. Breast Cancer Res (2013) 1.03
Using network biology to bridge pharmacokinetics and pharmacodynamics in oncology. CPT Pharmacometrics Syst Pharmacol (2013) 1.03
Optimal targeting of HER2-PI3K signaling in breast cancer: mechanistic insights and clinical implications. Cancer Res (2013) 1.03
Elevated PI3K signaling drives multiple breast cancer subtypes. Oncotarget (2011) 1.03
PTEN-deficient tumors depend on AKT2 for maintenance and survival. Cancer Discov (2014) 1.03
AKT facilitates EGFR trafficking and degradation by phosphorylating and activating PIKfyve. Sci Signal (2013) 1.03
Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models. Mol Cancer Ther (2013) 1.02
p38α MAPK pathway: a key factor in colorectal cancer therapy and chemoresistance. World J Gastroenterol (2014) 1.02
FoxO transcription factors promote AKT Ser473 phosphorylation and renal tumor growth in response to pharmacologic inhibition of the PI3K-AKT pathway. Cancer Res (2014) 1.02
Role of phosphatidylinositol-3-kinase pathway in head and neck squamous cell carcinoma. J Oncol (2012) 1.01
Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells. J Cell Mol Med (2013) 1.01
Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell (1999) 32.32
The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer (2002) 28.11
Defining the role of mTOR in cancer. Cancer Cell (2007) 21.63
A C. elegans mutant that lives twice as long as wild type. Nature (1993) 20.42
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 18.44
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer (2005) 16.73
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med (2005) 15.42
A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol (2008) 14.74
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science (2007) 10.60
The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer (2007) 8.05
Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature (1999) 7.66
Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science (1997) 7.07
A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell (2006) 6.96
The PI3K pathway as drug target in human cancer. J Clin Oncol (2010) 6.83
(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A (2009) 6.78
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature (2007) 6.56
The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A (2003) 6.37
Inhibitor hijacking of Akt activation. Nat Chem Biol (2009) 4.91
Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res (2002) 4.36
A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol Endocrinol (2000) 4.25
Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One (2008) 4.12
Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem J (2005) 3.58
Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg Med Chem Lett (2005) 3.50
The insulin-induced signalling pathway leading to S6 and initiation factor 4E binding protein 1 phosphorylation bifurcates at a rapamycin-sensitive point immediately upstream of p70s6k. Mol Cell Biol (1997) 2.66
Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res (2008) 2.62
Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Transl Med (2010) 2.42
Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene (2002) 2.34
Transcriptional feedback control of insulin receptor by dFOXO/FOXO1. Genes Dev (2005) 2.30
Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res (2010) 2.30
Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. Mol Cancer Ther (2005) 2.23
System-wide investigation of ErbB4 reveals 19 sites of Tyr phosphorylation that are unusually selective in their recruitment properties. Chem Biol (2008) 1.97
Conservation of an insulin response unit between mouse and human glucose-6-phosphatase catalytic subunit gene promoters: transcription factor FKHR binds the insulin response sequence. Diabetes (1999) 1.84
ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth. Oncogene (2001) 1.14
Insulin-like growth factor induces phosphorylation of immunoreactive insulin receptor substrate and its association with phosphatidylinositol-3 kinase in human thymocytes. J Exp Med (1995) 0.95
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 28.25
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med (2006) 25.67
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 18.44
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature (2010) 17.31
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science (2013) 10.87
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest (2008) 10.74
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol (2007) 9.29
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet (2007) 9.24
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol (2009) 8.46
Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell (2011) 7.32
(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A (2009) 6.78
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A (2010) 6.54
CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature (2008) 6.24
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res (2008) 5.82
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A (2007) 5.44
PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med (2002) 5.25
MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther (2010) 5.24
Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol (2003) 5.22
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol (2010) 4.94
Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol (2005) 4.82
The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell (2005) 4.48
4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell (2010) 4.48
Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One (2008) 4.12
mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov (2011) 4.05
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet (2013) 3.90
Epidermal growth factor receptor targeting in cancer. Semin Oncol (2006) 3.84
Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci (2007) 3.74
17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res (2002) 3.72
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res (2008) 3.70
Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem (2002) 3.70
Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol (2013) 3.57
Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res (2010) 3.54
TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell (2009) 3.38
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell (2012) 3.37
Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene (2003) 3.32
PCGF homologs, CBX proteins, and RYBP define functionally distinct PRC1 family complexes. Mol Cell (2012) 3.28
High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell (2007) 3.27
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res (2002) 3.14
Tumor adaptation and resistance to RAF inhibitors. Nat Med (2013) 3.11
Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol (2012) 3.07
PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov (2012) 2.89
Mutant BRAF melanomas--dependence and resistance. Cancer Cell (2011) 2.87
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol (2007) 2.80
Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling. Cancer Discov (2014) 2.79
An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol Cell (2007) 2.75
17AAG: low target binding affinity and potent cell activity--finding an explanation. Mol Cancer Ther (2003) 2.74
Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res (2008) 2.71
Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol (2004) 2.66
Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov (2013) 2.65
Resistance to BRAF inhibition in melanomas. N Engl J Med (2011) 2.58
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res (2007) 2.50
BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov (2012) 2.48
Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov (2012) 2.47
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res (2011) 2.43
Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene (2002) 2.34
Models from experiments: combinatorial drug perturbations of cancer cells. Mol Syst Biol (2008) 2.33
Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res (2004) 2.32
Targeting the Notch1 and mTOR pathways in a mouse T-ALL model. Blood (2009) 2.29
Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res (2012) 2.26
Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial. J Clin Oncol (2013) 2.26
Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol (2002) 2.25
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol (2002) 2.25
Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. J Nucl Med (2006) 2.24
Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res (2009) 2.22
Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med (2012) 2.19
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci U S A (2011) 2.18
Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology (2009) 2.17
Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. PLoS One (2007) 2.14
Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res (2003) 2.04
The evolving war on cancer. Cell (2011) 2.02
mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer. Sci Transl Med (2013) 1.98
Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest (2011) 1.97
Kruppel-like factor 2 (KLF2) regulates proinflammatory activation of monocytes. Proc Natl Acad Sci U S A (2006) 1.95
BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. J Clin Endocrinol Metab (2008) 1.95
Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res (2008) 1.94
Hsp90: a novel target for cancer therapy. Curr Top Med Chem (2006) 1.93
Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. Clin Cancer Res (2010) 1.92
A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Clin Cancer Res (2003) 1.83
Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. Proc Natl Acad Sci U S A (2011) 1.82
Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact? J Clin Oncol (2004) 1.82
An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo. Cancer Biol Ther (2010) 1.77